Lessons From Prospective Longitudinal Follow-up of a French APECED Cohort

Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome is a rare disease caused by biallelic mutations of the AIRE gene, usually presenting with the triad hypoparathyroidism-adrenal failure-chronic mucocutaneous candidiasis (CMC) and nonendocrine manifestations. The aim of this study was to determine the molecular profile of the AIRE gene, the prevalence of rare manifestations, and to characterize immunological disturbances in a French cohort.

Patients And Methods: A national, multicenter prospective observational study to collect genetic, clinical, biological, and immunological data (NCT03751683).

Results: Twenty-five patients (23 families) were enrolled. Eleven distinct AIRE variants were identified, 2 of which were not previously reported: an intronic variant, c.653-70G > A, and a c.1066del (p.Arg356GlyfsX22) variant (exon 9). The most common was the Finnish variant c.769C > T (16 alleles), followed by the variant c.967_979del13 (15 alleles), which seemed associated with a less severe phenotype. Seventeen out of 25 patients were homozygote. The median number of clinical manifestations was 7; 19/25 patients presented with the hypoparathyroidism-adrenal failure-CMC triad, 8/13 showed pulmonary involvement, 20/25 had ectodermal dystrophy, 8/25 had malabsorption, and 6/23 had asplenia. Fifteen out of 19 patients had natural killer cell lymphopenia with an increase in CD4+ and CD8+ T lymphocytes and an age-dependent alteration of B lymphocyte homeostasis compared with matched controls (P < .001), related to the severity of the disease. All tested sera (n = 18) were positive for anti-interferon-α, 15/18 for anti-IL-22 antibodies, and 13/18 for anti-IL-17F antibodies, without clear phenotypic correlation other than with CMC.

Conclusion: This first prospective cohort showed a high AIRE genotype variability, with 2 new gene variants. The prevalence of potentially life-threatening nonendocrine manifestations was higher with systematic screening. These manifestations could, along with age-dependent B-cell lymphopenia, contribute to disease severity. Systematic screening for all the manifestations of the syndrome would allow earlier diagnosis, supporting vaccination and targeted therapeutic approaches.

References

Piranavan P, Li Y, Brown E, Kemp E, Trivedi N . Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies. J Clin Endocrinol Metab. 2018; 104(2):550-556. DOI: 10.1210/jc.2018-01151. View

Pierce M, LaFranchi S, Pinter J . Characterization of Thyroid Abnormalities in a Large Cohort of Children with Down Syndrome . Horm Res Paediatr. 2017; 87(3):170-178. PMC: 5483988. DOI: 10.1159/000457952. View

Shum A, Alimohammadi M, Tan C, Cheng M, Metzger T, Law C . BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease. Sci Transl Med. 2013; 5(206):206ra139. PMC: 3882146. DOI: 10.1126/scitranslmed.3006998. View

Ahonen P, Miettinen A, Perheentupa J . Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab. 1987; 64(3):494-500. DOI: 10.1210/jcem-64-3-494. View

Gawalko M, Balsam P, Lodzinski P, Grabowski M, Krzowski B, Opolski G . Cardiac Arrhythmias in Autoimmune Diseases. Circ J. 2020; 84(5):685-694. DOI: 10.1253/circj.CJ-19-0705. View

Bjorses P, Halonen M, Palvimo J, Kolmer M, Aaltonen J, Ellonen P . Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am J Hum Genet. 2000; 66(2):378-92. PMC: 1288090. DOI: 10.1086/302765. View

Proust-Lemoine E, Saugier-Veber P, Wemeau J . Polyglandular autoimmune syndrome type I. Presse Med. 2012; 41(12 P 2):e651-62. DOI: 10.1016/j.lpm.2012.10.005. View

Mayer A, Ploix C, Orgiazzi J, Desbos A, Moreira A, Vidal H . Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism. J Clin Endocrinol Metab. 2004; 89(9):4484-8. DOI: 10.1210/jc.2004-0021. View

Proust-Lemoine E, Saugier-Veber P, Lefranc D, Dubucquoi S, Ryndak A, Buob D . Autoimmune polyendocrine syndrome type 1 in north-western France: AIRE gene mutation specificities and severe forms needing immunosuppressive therapies. Horm Res Paediatr. 2010; 74(4):275-284. DOI: 10.1159/000297714. View

10.

Gavalas N, Kemp E, Krohn K, Brown E, Watson P, Weetman A . The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2007; 92(6):2107-14. DOI: 10.1210/jc.2006-2466. View

11.

Tomar N, Kaushal E, Das M, Gupta N, Betterle C, Goswami R . Prevalence and significance of NALP5 autoantibodies in patients with idiopathic hypoparathyroidism. J Clin Endocrinol Metab. 2012; 97(4):1219-26. DOI: 10.1210/jc.2011-3093. View

12.

Bjorses P, Aaltonen J, Vikman A, Perheentupa J, Chiumello G, Dahl N . Genetic homogeneity of autoimmune polyglandular disease type I. Am J Hum Genet. 1996; 59(4):879-86. PMC: 1914815. View

13.

Tomar N, Gupta N, Goswami R . Calcium-sensing receptor autoantibodies and idiopathic hypoparathyroidism. J Clin Endocrinol Metab. 2013; 98(9):3884-91. DOI: 10.1210/jc.2013-2158. View

14.

Ferre E, Rose S, Rosenzweig S, Burbelo P, Romito K, Niemela J . Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016; 1(13). PMC: 5004733. DOI: 10.1172/jci.insight.88782. View

15.

Myhre A, Halonen M, Eskelin P, Ekwall O, Hedstrand H, Rorsman F . Autoimmune polyendocrine syndrome type 1 (APS I) in Norway. Clin Endocrinol (Oxf). 2001; 54(2):211-7. DOI: 10.1046/j.1365-2265.2001.01201.x. View

16.

Morimoto J, Matsumoto M, Miyazawa R, Yoshida H, Tsuneyama K, Matsumoto M . Aire suppresses CTLA-4 expression from the thymic stroma to control autoimmunity. Cell Rep. 2022; 38(7):110384. DOI: 10.1016/j.celrep.2022.110384. View

17.

Sendid B, Dotan N, Nseir S, Savaux C, Vandewalle P, Standaert A . Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan. Clin Vaccine Immunol. 2008; 15(12):1868-77. PMC: 2593178. DOI: 10.1128/CVI.00200-08. View

18.

Kubala S, Do H, Ferre E, Schrump D, Olivier K, Walls J . Fatal autoimmune pneumonitis requiring bilobectomy and omental flap repair in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Respir Med Case Rep. 2021; 33:101476. PMC: 8349050. DOI: 10.1016/j.rmcr.2021.101476. View

19.

Popler J, Alimohammadi M, Kampe O, Dalin F, Dishop M, Barker J . Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatr Pulmonol. 2011; 47(1):84-7. DOI: 10.1002/ppul.21520. View

20.

Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R . Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2008; 93(11):4389-97. DOI: 10.1210/jc.2008-0935. View